Compare Synopsys, Inc. (SNPS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Synopsys, Inc. vs Zoetis Inc — how do they compare? Synopsys, Inc. trades at $412.4 (market cap $78.68B), while Zoetis Inc trades at $73.68 (market cap $31.14B). The key difference: Synopsys, Inc. is far larger — about 2.5× Zoetis Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals.
| SNPS | ZTS | |
|---|---|---|
Market Cap | $78.68B | $31.14B |
Sector | Technology | Health |
52-Week High | $625.80 | $156.76 |
52-Week Low | $372.33 | $71.91 |
Enterprise Value | $87.04B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Synopsys (SNPS) trades at $412.06, up 0.09% on the day, with a bearish technical signal despite recent earnings beats. The stock shows high valuation ratios (P/E 94.03, P/S 8.68) and a net income margin of 8.91%. Recent news highlights AI-driven growth potential from the Ansys acquisition and agentic EDA workflows, though cash flow trends show volatility with a net outflow of $1.01B in 2025.
Outlook remains positive with analyst consensus favoring Buy (82.76%) and a $551 price target, but risks include elevated valuation, competitive pressures, and integration challenges from acquisitions. The stock offers growth exposure to semiconductor design software but requires monitoring of execution and market sentiment shifts.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
